Correlation between the expression of excision repair cross complementing 2 and P53 and platinum -based chemotherapy sensitivity in patients with advanced gastric cancer
10.13699/j.cnki.1001-6821.2015.23.010
- VernacularTitle:晚期胃癌化疗中含铂类药物敏感性与切除修复交叉互补基因2和 P53蛋白表达的相关性
- Author:
Chang-Xia HE
1
;
Kang-Sheng GU
Author Information
1. 马鞍山市人民医院 肿瘤介入病区
- Keywords:
advanced liver cancer;
excision repair cross complementing 2;
platinum chemotherapy;
progression-free survival time;
overall sur-vival time
- From:
The Chinese Journal of Clinical Pharmacology
2015;(23):2309-2310,2313
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of the excision re-pair cross complementing 2( ERCC2) and P53 in the tissue of advanced liver cancer, and the relationship between the expression and the scheme with platinum chemotherapy curative effect and prognosis.Methods A total of 56 cancer patients were given oxaliplatin 135 mg? m-2 and cisp-latin 75 mg? m-2 for treatment of 2-4 recycle.Use the immunohisto-chemistry to detect the expression of the ERCC2 and P53 in the tissue of advanced liver cancer, give a platinum-based drugs chemotherapy, and then evaluate the chemotherapeutic effect, progression -free survival time and overall survival time.Results The expression of ERCC2 and P53 was associated with curative effect of platinum chemotherapy (P<0.05).The overall survival time of patients with positive expression of ERCC2 and P53 was longer than that of patients with the negative expression ( P<0.05 ) , and the progression-free survival time of patients with P53 positives was extended ( P <0.05 ) .Conclusion The expression of the ERCC2 and P53 was associated with the curative effect of platinum chemo-therapy in the gastric carcinoma patients, which can be used as a detection index to evaluate the prognosis of the gastric cancer by chemotherapy.
